17,261 trials
Prostatic Neoplasms
Primary: Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12 — 10; 25 Participants
Bone Resorption · Osteoporosis
Primary: Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline — 0.51; 0.51 percentage change
Lymphoma
Primary: Progression-free Survival — 18 participants
Hepatitis C
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 - Full Analysis Set — 6.38843; 6.67823; 6.66254; 6.42047 log10 IU/mL…
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Endometriosis
Primary: Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation — -56.86; -77.72; -36.69; -66.84 percentage of serum AMH change
Severe Sepsis · Septic Shock
Primary: Safety and Tolerability of AZD9773 — 7; 7; 6; 1 Participants
Fecal Incontinence
Primary: Fecal Incontinence Incidence From Baseline (Pre-treatment) Through 24 Months Post-treatment — 6.9; 3.0; 3.7; 3.7 Number of FI episodes/14 day period
Esophageal Cancer
Primary: Complete Pathologic Response — 12 participants
Urinary Bladder Neoplasms
Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants
Severe Sepsis
Primary: Change From Baseline in Creatinine Values — -78.6; -196.8; -25.1; -10.9 μmol/L
Leukemia · Lymphoma
Primary: Participants With Objective Response — 0; 1; 13 Participants
Alcohol Abuse · Cocaine Abuse · Marijuana Abuse
Primary: Percentage of Days Used Drugs or Alcohol — 18; 21; 6; 7 percentage of days — p=0.88
Breast Cancer
Primary: Median Time to Progression — 149 Days
Superficial Bladder Cancer
Primary: Complete Tumor Response Defined as the Absence of New Tumors — 64.1 percentage of participants